Microcap Ledger Xenetic Biosciences, Inc. $XBIO
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Framingham, MA
- Fiscal year end
- December 31
- Shares outstanding
- 2,343,181 [10-Q 2026-08-06]
What the company doesAI summary of filing
Xenetic Biosciences is a clinical-stage biopharmaceutical company developing immuno-oncology technologies for difficult-to-treat cancers. The company's primary focus is advancing its DNase technology, which targets neutrophil extracellular traps to improve outcomes of existing cancer treatments including immunotherapies, chemotherapy, and radiotherapy. The systemic DNase program is initially targeting pancreatic cancer, colorectal cancer, and other solid tumors through collaborations with research institutions and clinical trial partners. The company generates revenue from royalty payments on its PolyXen platform technology licensed to industry partners, including approximately $3.0 million in royalties from Takeda in 2025. [10-K 2026-03-12]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $1.47M | −$1.39M | −$1.41M | $6.47M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $2.98M | −$2.68M | −$2.29M | $7.88M | [10-K 2026-03-12] |
| FY ended Dec 2024 | $2.50M | −$3.96M | −$2.82M | $6.17M | [10-K 2026-03-12] |
- Quarterly cash burn
- −$705.9K
- Cash runway Estimate
- ~27.5 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-04-18 | 1,542,139 | [10-K/A 2025-05-13] |
| 2025-05-02 | 1,542,139 | [10-Q 2025-05-13] |
| 2025-08-07 | 1,542,139 | [10-Q 2025-08-12] |
| 2025-11-07 | 2,291,056 | [10-Q 2025-11-12] |
| 2026-03-06 | 2,291,056 | [10-K 2026-03-12] |
| 2026-04-17 | 2,291,056 | [10-K/A 2026-04-24] |
| 2026-05-08 | 2,291,056 | [10-Q 2026-05-12] |
| 2026-07-31 | 2,343,181 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2024-10-21; declared effective 2024-11-01 [S-3 2024-10-21]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-04-21 | Parslow James F | grant | 100,000 | — | [4 2026-04-23] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-23 | 8-K | Regulation FD disclosure |
| 2026-09-18 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-09-16 | 8-K | Material agreement entered; Unregistered sale of equity; Regulation FD disclosure |
| 2026-08-07 | 8-K | Results of operations |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-05-29 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-13 | 8-K | Results of operations |
| 2026-05-12 | 10-Q | Quarterly report |
| 2026-04-24 | 10-K/A | Amended report |
| 2026-04-24 | 8-K | Director or officer change |
| 2026-03-13 | 8-K | Results of operations |
Alerts for $XBIO
Email me when Xenetic Biosciences, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.